Lobbying

Averitas Pharma's latest lobbying report covers Q4 2023, at $60K. Its first report covers Q4 2022; the issues it reports most are Medicare/Medicaid.

Averitas Pharma

Latest quarter
No record
Q3 2026 · 0 reports
Last 12 months
$0
Last 4 quarters
vs last quarter
No record
Q3 2026 against the quarter before
First report
Q4 2022
The first quarter a report named it

Lobbying by quarter

Averitas Pharma lobbying by quarter
Averitas Pharma lobbying by quarter
QuarterAmountReports
Q4 2022$60K1
Q1 2023$60K1
Q2 2023$60K1
Q3 2023$60K1
Q4 2023$60K1
Q1 2024$00
Q2 2024$00
Q3 2024$00
Q4 2024$00
Q1 2025$00
Q2 2025$00
Q3 2025$00
Q4 2025$00
Q1 2026$00
Q2 2026$00
Q3 2026$00

By issue

  • Medicare and Medicaid$300K · 5 reports

An issue's amount splits each report's amount equally over the issues the report lists.

Who was lobbied

  • HOUSE OF REPRESENTATIVES4 reports
  • SENATE4 reports

Firms it paid

Firm
Thorn Run Partners$300K5 quarters

Former officials lobbying for it

Former position
JESSIE HOWE BRAIRTONSenior Legislative Asst/Legislative Asst, Rep. Lamar Smith; LC/Asst, Senate Special Aging CommitteeQ4 2023

Lobbying reports

Filed by
24/01/22for Q4 2023Thorn Run Partners$60K
23/10/18for Q3 2023Thorn Run Partners$60K
23/07/19for Q2 2023Thorn Run Partners$60K
23/04/20for Q1 2023Thorn Run Partners$60K
23/01/19for Q4 2022Thorn Run Partners$60K